Etrasimod IBD Trial


A worldwide, Phase 3 clinical program evaluating etrasimod – an oral, selective, sphingosine 1 phosphate (S1P) receptor modulator – for the treatment of moderately to severely active ulcerative colitis.

Rise Up Against UC. Join Elevate

Patients may be able to take part in the clinical program if they*:

  • Are 16 to 80 years of age
  • Were diagnosed with moderately to severely active ulcerative colitis at least 3 months ago
  • Did not respond to, are no longer responding to, or did not tolerate another UC therapy

For more information please visit

*Other eligibility criteria may apply